Authors
Latest:
Conservative management feasible for uncomplicated renal colic patients with positive urine cultures“Though septic stones are well recognized as a medical emergency, patients with uncomplicated renal colic (without systemic inflammatory responses or renal impairment) and positive urine cultures pose a dilemma in management considerations,” the investigators explained in their abstract.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
2-year data show continued enfortumab vedotin efficacy in cisplatin-ineligible MIBCUpdated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.
Latest:
Expert outlines advantages of batteryless sacral neuromodulation device“For someone that might be looking at getting into sacral neuromodulation, and has had some reluctance in the past, this does simplify the procedure somewhat," says Colin Goudelocke, MD.
Latest:
Olaparib plus abiraterone/prednisone linked with improved PFS in mCRPCThe median PFS was 39 months (95% CI, 22-not reached [NR]) in arm 3 compared with 8.4 months (95% CI, 2.9-17.0) in arm 1 and 14 months (95% CI, 8.4-20.0) in arm 2.
Latest:
Apalutamide combo hits high 2-year RFS rate in prostate cancerTreatment with apalutamide and androgen deprivation therapy led to a 2-year biochemical recurrence-free survival rate of 100% in patients with high-risk, post-prostatectomy prostate cancer.
Latest:
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says Nedim Ruhotina, MD.
Latest:
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal TherapyPanelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Latest:
AHN Becomes the First Health System in Western Pennsylvania to Offer AI-Powered Therapy to Treat Enlarged Prostate“We are incredibly proud to lead the way in Western Pennsylvania by introducing Aquablation therapy to patients in our region who are experiencing advanced stage BPH,” says Goutham Vemana, MD.
Latest:
Eric Jonasch, MD, on phase 1/2 trial of 177Lu-girentuximab combination in ccRCC“We really want to understand whether by using this beta emitter, together with the combination of cabazantinib and the nivolumab, we're getting better outcomes than we would expect with the doublet alone,” says Eric Jonasch, MD.
Latest:
Key Challenges in the Administration of Leuprolide for Advanced/Metastatic Prostate CancerIn the second article of the series, Paul Sieber, MD, shares best practices for the administration of leuprolide in patients with advanced/metastatic prostate cancer.
Latest:
The urologist in the world of precision medicine"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.
Latest:
The status and future direction of advanced urine testing: multiplex PCR"Given that PCR testing may have a benefit for specific cohorts, it is recommended that more clinical evidence be provided to better guide Medicare in defining 'medical necessity,' ” write Stephanie Gleicher, MD, MPH, and Roger R. Dmochowski MD, MMHC, FACS.
Latest:
EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OABExperts close their panel on OAB by identifying treatment pathways for patients who have an unsatisfactory response to third-line therapy.
Latest:
Dr. Cheryl Iglesia highlights the evolving treatment paradigm for overactive bladder“New data indicate that long-term use of some of these overactive bladder drugs is not good for cognitive function,” explains Iglesia.
Latest:
Genomic and imaging advances drive precision medicine progress in prostate cancerRohan Garje, MD, discusses precision medicine in metastatic prostate cancer, including genomic testing, targeted therapies, and theragnostics.
Latest:
Darolutamide safety in nmCRPC sustained with prolonged exposureSafety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.
Latest:
Study assesses impact of health literacy on chronic pelvic painAddressing the gaps in health literacy may lead to improvement in health outcomes and health care disparities among patients with chronic pelvic pain.
Latest:
Automated medical coding benefits both the practice and the patientsWhen you add automation, your medical coding not only improves your margins but also plays a key role in improving patient care.
Latest:
Multidisciplinary Care for Patients With mCRPCIn the third article of this series, Paul E. Dato, MD, provides comprehensive insights on the multidisciplinary care of patients with metastatic castration-resistant prostate cancer.
Latest:
What the SWIU Census reveals about the state of women in urology"As the number of women urologists continues to increase, the field of urology must pay attention to their needs and professional satisfaction as they will constitute an increasing proportion of the future urologic work force," writes Lourdes Guerrios Rivera, MD, MSc.
Latest:
Urologic research and COVID-19: Unmasking the silver liningIn this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
Latest:
Treatment at high-volume facilities linked to improved survival in node-positive prostate cancerThe improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.
Latest:
“Shooting for the Moon” means reducing metastatic prostate cancer diagnoses“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.
Latest:
Clinical Pearls and Future of Bladder Cancer TreatmentEric A. Singer, MD, MA, FACS, looks to the future of bladder cancer treatment and offers advice for community urologists and urologic oncologists treating patients with the disease.
Latest:
Urologic implications of Lynch syndromeResearch indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.
Latest:
Is video-based research feasible for pediatric urology visits?"This first paper was really to show that our research methodology was feasible and acceptable with pediatric urology patients and families. We've done that, and now we have a huge corpus of data that we can further analyze through empirical studies," says Francesca A. Williamson, PhD.
Latest:
Considerations for palliative care in urologic oncologyBenefits include improved quality of life and symptom management.
Latest:
United Urology Group and its affiliate practices and Prostate Centers USA® are collaborating to revolutionize men's health care with minimally invasive solutionsThe inclusion of PAE in the American Urological Association BPH Guidelines offers a non-surgical alternative that can provide long-term relief with minimal downtime and fewer complications, according to the United Urology Group.
Latest:
Triplet therapy including darolutamide should be standard of care in mCSPC, data indicateResults of the ARASENS trial (NCT02799602) demonstrated that darolutamide plus ADT and docetaxel prolonged overall survival regardless of disease volume or risk.
